

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>  (Use as many sheets as necessary)				<b>Complete If Known</b> <table border="1" style="width: 100%; border-collapse: collapse;"> <tr> <td style="width: 50%;">Application Number</td> <td>10/516,757</td> </tr> <tr> <td>Filing Date</td> <td>December 4, 2004</td> </tr> <tr> <td>First Named Inventor</td> <td>Rabussay, Dietmar</td> </tr> <tr> <td>Art Unit</td> <td>TBA</td> </tr> <tr> <td>Examiner Name</td> <td>TBA</td> </tr> </table>		Application Number	10/516,757	Filing Date	December 4, 2004	First Named Inventor	Rabussay, Dietmar	Art Unit	TBA	Examiner Name	TBA
Application Number	10/516,757														
Filing Date	December 4, 2004														
First Named Inventor	Rabussay, Dietmar														
Art Unit	TBA														
Examiner Name	TBA														
Sheet	1	of	2	Attorney Docket No: GTI-1490-US											

US PATENT DOCUMENTS					
Examiner Initial *	Cite No	Document Number	Publication Date	Name of Patentee or Applicant of Cited Document	Filing Date If Appropriate
	1	3523907	08/11/1970	VRANCKEN et al	
	2	5171568	12/15/1992	BURKE et al	

FOREIGN PATENT DOCUMENTS					
Examiner Initials*	Cite No	Foreign Patent Document	Publication Date	Name of Patentee or Applicant of cited Document	T <sup>2</sup>
	3	WO 89/04669	06/01/1989	HOUGHTON et al	
	4	WO 90/11089	10/04/1990	HOUGHTON et al	
	5	WO 90/14436	11/29/1990	HOUGHTON et al	
	6	WO 90/14837	12/13/1990	VAN NEST et al	

OTHER DOCUMENTS -- NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	7	BAER et al, "DNA Sequence and Expression of the B95-8 Epstein Barr Virus Genome," <i>Nature</i> 310:207-211 (1984)	
	8	CHEE et al, "Analysis of the protein-coding content of the sequence of human cytomegaloviruses strain AD169," <i>Curr Top Microbiol Immunol.</i> 154:125-169	
	9	DAVISON et al, "The complete DNA sequence of varicella-zoster virus," <i>J. Gen. Virol.</i> 67:1759-1816 (1986)	
	10	DOE et al, "Induction of HIV-1 envelope (gp120)-specific cytotoxic T lymphocyte responses in mice by recombinant CHO cell-derived gp120 is enhanced by enzymatic removal of N-linked glycans," <i>Eur. J. Immunol.</i> 24(10):2369-2376 (1994)	
	11	ERICKSON et al "Hepatitis C virus-specific CTL responses in the liver of chimpanzees with acute and chronic hepatitis," <i>J. Immunol.</i> 151:4189-4199 (1993)	
	12	HOUGHTON et al, "Molecular biology of the hepatitis C viruses: implications for diagnosis, development and control of viral disease," <i>Hepatology</i> 14(2):381-388 (1991)	
	13	JEFFERY et al, "The preparation and characterization of poly(lactide-co-glycolide) microparticles. II. The entrapment of a model protein using a (water-in-oil)-in-water emulsion solvent evaporation technique," <i>Pharm Res.</i> 10(3):362-368 (1993)	
	14	KAWAOKA et al, "Molecular characterization of a new hemagglutinin, subtype H14, of influenza A virus," <i>Virology</i> 179:759-767 (1990)	
	15	MCGECH et al, "The Complete DNA Sequence of the Long Unique Region in the Genome of Herpes Simplex Virus Type," <i>J. Gen. Virol.</i> 69:1531-1574 (1988)	
	16	MIZUSHIMA et al, "pEF-BOS, a Powerful Mammalian Expression Vector," <i>Nucleic Acids Research</i> 18(17):5322 (1990)	
	17	MODROW et al, "Computer-assisted analysis of envelope protein sequences of seven human immunodeficiency virus isolates: prediction of antigenic epitopes in conserved and variable regions," <i>J. Virology</i> 61:570-578 (1987)	
	18	MORIARTY et al, "Expression of the Hepatitis B Virus Surface Antigen Gene in Cell Culture by Using a Simian Virus 40 Vector," <i>Proc. Natl. Acad. Sci. (USA)</i> 78(4):2606-2610 (1981)	
	19	O'HAGAN et al, "Long-term antibody responses in mice following subcutaneous immunization with ovalbumin entrapped in biodegradable microparticles," <i>Vaccine</i> 11:965-969 (1993)	
	20	OGAWA et al, "A new technique to efficiently entrap leuprolide acetate into microcapsules of polylactic acid or copoly(lactic/glycolic) acid," <i>Chem. Pharm. Bull.</i> 36:1095-1103 (1988)	
	21	OTT et al, "MF-59—Design and Evaluation of a Safe and Potent Adjuvant for Human Vaccines," in POWELL et al, <i>Vaccine Design: The Subunit and Adjuvant Approach</i> Plenum Press, New York pp. 277-296 (1995)	
	22	REMINGTON <i>The Science and Practice of Pharmacy</i> , Mack Publishing Company, Easton, PA, 19 <sup>th</sup> Edition (1995)	

EXAMINER

DATE CONSIDERED

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO  <b>INFORMATION DISCLOSURE STATEMENT BY APPLICANT</b>   (Use as many sheets as necessary)					
				<i>Complete If Known</i>	
				Application Number	10/516,757
				Filing Date	December 4, 2004
				First Named Inventor	Rabussay, Dietmar
				Art Unit	TBA
				Examiner Name	TBA
Sheet	2	of	2	Attorney Docket No: GTI-1490-US	

	23	VAN NEST et al, "Advanced adjuvant formulations for use with recombinant subunit vaccines," in BROWN et al, <i>Vaccines 92, Modern Approaches to New Vaccines</i> Cold Springs Harbor Laboratory Press pp. 57-62 (1992)	
	24	WEBSTER et al, "Antigenic variation among type A influenza viruses," p. 127-168. In: alese et al (ed.), <i>Genetics of influenza viruses</i> . Springer-Verlag, New York	

EXAMINER

DATE CONSIDERED

Substitute Disclosure Statement Form (PTO-1449)

\* EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional) 2 Applicant is to place a check mark here if English language Translation is attached